Pacific Biosciences (PACB) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Pacific Biosciences of California (PACB) reported revenue of $39.77 million for the quarter ended June 2025, marking a year-over-year increase of 10.4% and exceeding the Zacks Consensus Estimate by 9.06% [1] - The company posted an EPS of -$0.13, an improvement from -$0.20 a year ago, with a surprise of 27.78% compared to the consensus estimate of -$0.18 [1] Revenue Breakdown - Revenue from Product - Instrument was $14.15 million, slightly below the average estimate of $10.9 million, reflecting a year-over-year decline of 3.7% [4] - Revenue from Product was $33.08 million, surpassing the average estimate of $31.18 million, with a year-over-year increase of 4.2% [4] - Revenue from Service and other reached $6.68 million, significantly exceeding the estimated $5.09 million, representing a year-over-year increase of 56.6% [4] - Revenue from Product - Consumable was $18.93 million, below the average estimate of $20.29 million, but still showing a year-over-year growth of 11.4% [4] Stock Performance - Shares of Pacific Biosciences have declined by 6.8% over the past month, contrasting with a 1.2% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]